Increased epithelial permeability in pulmonary fibrosis in relation to disease progression

Goh, Nicole; Anagnostopoulos, Constantinos; Hansell, D.M.; Hoyles, Rachel; Sato, Hikari; Denton, CP; Black, CM; Bois, Roland M. du; Wells, AU

doi:10.1183/09031936.00010910

Cited by 40 publications

(22 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In this regard, a staging system using disease extent on HRCT with an ancillary role for the lung function test in ''indeterminate'' cases [104,105], and a series of markers of epithelial injury and epithelial cell damage have been implemented [106][107][108][109]. Recently, increased levels of IL-6 have been proposed as marker of a decline in FVC and/or DLCO within the first year, and of death within the first 30 months in patients with mild disease [110].…”

Section: Advances In Understanding the Pathogenetic Mechanisms Of Ipfmentioning

confidence: 98%

Interstitial lung disease

Αντωνίου

Margaritopoulos

Tomassetti

et al. 2014

European Respiratory Review

216

137

View full text Add to dashboard Cite

Interstitial lung diseases are a group of diffuse parenchymal lung disorders associated with substantial morbidity and mortality. Knowledge achieved in recent years has resulted in the publication of the new classification of idiopathic interstitial pneumonias, according to which there are three groups: major, rare and unclassified. The novelty of the new classification comes from the fact that difficult to classify entities can be treated according to the disease behaviour classification. Idiopathic pulmonary fibrosis is the most lethal amongst the interstitial lung diseases and presents high heterogeneity in clinical behaviour. A number of biomarkers have been proposed in order to predict the course of the disease and group patients with the same characteristics in clinical trials. Early diagnosis and disease stratification is also important in the field of other interstitial lung diseases.

show abstract

Section: Advances In Understanding the Pathogenetic Mechanisms Of Ipfmentioning

confidence: 98%

Interstitial lung disease

Αντωνίου

Margaritopoulos

Tomassetti

et al. 2014

European Respiratory Review

216

137

View full text Add to dashboard Cite

show abstract

“…The increased clearance of technetium-labeled diethylene triamine pentaacetate (99mTc-DTPA) aerosol from the lungs of patients with SSc-ILD is indicative of a breached epithelial barrier and is associated with more rapid decline in FVC [20, 21], independently of disease severity. Lung epithelium-specific proteins leaking into the circulation may thus represent potential biomarkers of alveolar epithelial damage.…”

Section: Alveolar Epithelial Proteinsmentioning

confidence: 99%

Circulating Biomarkers of Interstitial Lung Disease in Systemic Sclerosis

Lota

Renzoni

2012

International Journal of Rheumatology

View full text Add to dashboard Cite

Interstitial lung disease (ILD) is a major cause of morbidity and mortality in patients with systemic sclerosis (SSc). Although a large proportion of SSc patients have only limited interstitial involvement with an indolent course, in a significant minority ILD is progressive, requiring prompt treatment and careful monitoring. One of the main challenges for the clinician treating this highly variable disease is the early identification of patients at risk of progressive ILD, while avoiding potentially toxic treatments in those whose disease is inherently stable. Easily available and repeatable biomarkers that allow estimation of the risk of ILD progression and early response to treatment are highly desirable. In this paper, we review the evidence for circulating biomarkers with potential roles in diagnosis, monitoring of disease activity, or determining prognosis. Peripheral blood biomarkers offer the advantages of being readily obtained, non-invasive, and serially monitored. Several possible candidates have emerged from studies performed so far, including SP-D, KL-6, and CCL18. Presently however, there are few prospective studies evaluating the predictive ability of prospective biomarkers after adjustment for disease severity. Future carefully designed, prospective studies of well characterised patients with ILD, with optimal definition of disease severity and outcome measures are needed.

show abstract

“…Abnormal angiogenesis has furthermore been linked to the development of fibrotic disorders of the lung [7]. Together, these changes result in an increase in the permeability of the alveolar capillary barrier, which can be detected clinically by increased diethylene triamine penta-acetic acid clearance [8]. Increased alveolar capillary barrier permeability may also be associated with early mortality in IPF [9].…”

mentioning

confidence: 99%

Metalloproteinases in idiopathic pulmonary fibrosis

2011

View full text Add to dashboard Cite

In this article, we outline the current state of knowledge about the balance between collagen production and degradation in idiopathic pulmonary fibrosis (IPF). The dysregulated action of metalloproteinases implicated in IPF may play a central role in IPF pathogenesis. Inhibiting metalloproteinases in IPF may, therefore, have therapeutic potential, but our knowledge of their pathophysiological role is held back by limited animal models and the lack of specific inhibitors.

show abstract

Increased epithelial permeability in pulmonary fibrosis in relation to disease progression

Cited by 40 publications

References 30 publications

Interstitial lung disease

Interstitial lung disease

Circulating Biomarkers of Interstitial Lung Disease in Systemic Sclerosis

Metalloproteinases in idiopathic pulmonary fibrosis

Contact Info

Product

Resources

About